KTX-049

KTX-049 is a preclinical-stage small molecule heterobifunctional protein degrader (PROTAC) developed by Kymera Therapeutics. It is designed to target and induce the proteasomal degradation of MDM2 (Mouse Double Minute 2 homolog), an E3 ubiquitin ligase that acts as the primary negative regulator of the p53 tumor suppressor. By eliminating MDM2 protein, KTX-049 facilitates the stabilization and reactivation of p53, leading to cell cycle arrest and apoptosis in TP53 wild-type cancer cells. Preclinical data, including studies in collaboration with the Dana-Farber Cancer Institute, have demonstrated that KTX-049 possesses superior potency compared to traditional MDM2 small molecule inhibitors, particularly in Merkel cell carcinoma (MCC) models. The compound has shown effectiveness even with brief exposure, highlighting its potential as a highly potent therapeutic for p53-mediated tumor suppression.